IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
Open accessThe DOI matches its Crossref record.
Abstract
Background and Aims: Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn’s disease, patients entered a long-term extension for up to 5 years from induction. Efficacy through 152 and safety through 156 weeks are reported. Methods: At IM-UNITI Week 44, 567 ustekinumab-treated patients entered the long-term extension and continued to receive blinded subcutaneous ustekinumab on their assigned dose interval, without any subsequent dose adjustment. Placebo-treated patients discontinued after study unblinding [after IM-UNITI Week 44 analyses]. Efficacy data in the long-term extension [LTE] were collected every 12 weeks [q12w] before unblinding and then at q12w/q8w dosing visits. Results: Through Week 156, 29.6% of ustekinumab-treated patients discontinued. In an intent-to-treat analysis of randomised patients from IM-UNITI Weeks 0–152, 38.0% of ustekinumab induction responders receiving the drug q12w and 43.0% q8w were in remission at Week 152. Among patients entering the long-term extension in their original randomised groups, 61.9% of q12w and 69.5% of q8w patients were in remission at Week 152. Across all ustekinumab-treated patients [randomised and non-randomised] entering the long-term extension, remission rates at Week 152 were 56.3% and 55.1% for q12w and q8w, respectively. Safety events [per 100 patient-years] were similar among all ustekinumab-treated patients entering the long-term extension and placebo [overall adverse events 389.70 vs 444.17; serious adverse events, 18.97 vs 19.54; serious infections, 4.21 vs 3.97]. Rates of antibodies to ustekinumab through Week 156 remained low, 4.6% in all randomised ustekinumab-treated patients; lowest among patients in the original randomised q8w group [2/82, 2.4%]. Conclusions: Continued treatment with subcutaneous ustekinumab maintained clinical response and remission through 3 years in a majority of patients who responded to induction therapy and was well-tolerated. ClinicalTrials.gov number NCT01369355.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,106
The Gut Microbiota in Inflammatory Bowel Disease
Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.733992 · Cited by 591
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., Warusavitarne, J., Agrawal, M., Allocca, M., Atreya, R., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjae091 · Cited by 388
Blockade of IL-23: What is in the Pipeline?
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab185 · Cited by 93
Self-citation
Metadata
- Authors
- Hanauer, S. B., Sandborn, W. J., Feagan, B. G., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Adedokun, O. J., Sands, B. E., Rutgeerts, P., de Villiers, W. J. S., Colombel, J.-F., & Ghosh, S.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06-03
- Volume
- 14
- Issue
- 1
- Pages
- 23-32
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2948759662
- Cited by
- 213
- References
- 0
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjz110
- The paper
- Hanauer, S. B., Sandborn, W. J., Feagan, B. G., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Adedokun, O. J., Sands, B. E., Rutgeerts, P., de Villiers, W. J. S., Colombel, J.-F., & Ghosh, S. (2020). IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjz110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.